Breast Cancer With High TIL Levels: Skip the Trastuzumab?Breast Cancer With High TIL Levels: Skip the Trastuzumab?
A provocative study suggests that HER2 breast cancer patients with high levels of stromal tumor infiltrating lymphocytes may not need trastuzumab (Herceptin). Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 10, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer
Dateline City: SAN ANTONIO Collaborative Trial is First to Investigate an Anti-PD-1 Therapy, Pembrolizumab, Combined with Trastuzumab Study to Explore Whether New Approach May Reverse Trastuzumab Resistance in Cancer with Significant Unmet Need SAN ANTONIO--(BUSINESS WIRE)--The International Breast Cancer Study Group (IBCSG), Breast International Group (BIG), and Merck, known as MSD outside the United States and Canada, today announced the opening of the PANACEA study, a global collaborative study exploring a new way to treat HER...
Source: Merck.com - Research and Development News - December 10, 2014 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news

Immune function marker does not predict benefit of trastuzumab in HER-2+ breast cancer
(Mayo Clinic) A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker -- the quantity of tumor-infiltrating lymphocytes in a biopsy -- appears irrelevant when trastuzumab is used. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2014 Category: Cancer & Oncology Source Type: news

Data published on ANG4043, anti-HER2 monoclonal antibody for treatment of brain metastases
(The Yates Network) Data published in Molecular Cancer Therapeutics, entitled 'ANG4043, a Novel Brain-penetrant Peptide-mAb Conjugate, is Efficacious against HER2-positive Intracranial Tumors in Mice,' demonstrates that ANG4043, a peptide-monoclonal antibody conjugate, entered the brain at therapeutic concentrations, resulting in significantly prolonged survival in mice. The antibody is directed against HER2, which is the protein targeted by Herceptin. The data published shows that this technology to cross the blood brain barrier is applicable to biologics such as mAbs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2014 Category: Cancer & Oncology Source Type: news

Immune Function Marker Does Not Predict Benefit of Trastuzumab in HER-2+ Breast Cancer Patients, Study Finds
JACKSONVILLE, Fla. — A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker — the quantity of tumor-infiltrating lymphocytes (S-TILs) in a biopsy — appears irrelevant when [...] (Source: Mayo Clinic Jacksonville News)
Source: Mayo Clinic Jacksonville News - December 8, 2014 Category: Hospital Management Source Type: news

SOFT Trial Landing at SABCSSOFT Trial Landing at SABCS
Dr Kathy Miller's preview of SABCS 2014 spotlights key data in triple-negative, HER2+, and local-regional disease as well as the much-anticipated results from the SOFT trial. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 1, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Prognostic role found for miR-21 expression in triple-negative breast cancer
(Elsevier Health Sciences) 'Triple-negative' breast cancer occurs in patients whose cells do not express receptors for estrogen, progesterone, and/or human epidermal growth factor receptor 2 (ER/PR/HER2). Because of the absence of these predictive biomarkers, treatment assignment can be difficult. Now, researchers report that high levels of the microRNA miR-21 in the tumor microenvironment, but not in the tumor epithelia, are associated with worse clinical outcomes for patients with triple-negative breast cancer, thus identifying a possible triple-negative breast cancer prognostic biomarker. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2014 Category: Global & Universal Source Type: news

Synthon begins dosing in Phase I trial of SYD985 to treat metastatic solid tumours
Netherlands-based Synthon Biopharmaceuticals (Synthon) has dosed first patients in a Phase I trial of its investigational anti-HER2 antibody-drug conjugate (ADC), SYD985, to treat metastatic solid tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - November 27, 2014 Category: Pharmaceuticals Source Type: news

FDA Approves Biosimilar Ogivri for Breast, Stomach Cancers
Ogivri is approved to treat HER2 + breast and gastric or gastroesophageal junction adenocarcinoma cancers (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Gastroenterology, Gynecology, Internal Medicine, Oncology, Pharmacy, Institutional, Source Type: news

New Drug Combo Ups Survival in HER2/neu Uterine Serous Cancer
Adding intravenous trastuzumab to carboplatin - paclitaxel increased progression - free survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Use of Image Analysis to ID HER2 Status in Breast Cancer Outlined
Guideline addresses use of quantitative image analysis to interpret HER2 immunohistochemistry (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Journal, Source Type: news

Potential target for treating triple-negative breast cancer identified
A protein that could prevent metastasis and recurrence of breast cancer has been identified by researchers. So-called "triple-negative" breast cancer represents between 12 and 17 percent of all breast cancers. It derives its name from the lack of receptors for estrogen, progesterone and Her2. The absence of these receptors rules out proven hormone therapies such as tamoxifen. Triple-negative breast cancer can be more aggressive and is more likely to recur than other breast cancers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 29, 2014 Category: Science Source Type: news

Should PIK3CA Inform Therapy Choice in Breast Cancer?Should PIK3CA Inform Therapy Choice in Breast Cancer?
Dr Lidia Schapira reports on a study showing that PIK3CA mutations may indicate trastuzumab resistance in HER2+ breast cancer but cautions use of the biomarker as a basis for clinical decisions. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 29, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

Perjeta and Kadcyla HER2 Positive Breast Cancer Market to 2020 in a...
This report focuses on the current treatment landscape, unmet...(PRWeb October 22, 2014)Read the full story at http://www.prweb.com/releases/2020-perjeta-kadcyla-her2/positive-breast-cancer/prweb12268571.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 23, 2014 Category: Pharmaceuticals Source Type: news

Trastuzumab (Herceptin) Continues to Show Life-Altering Benefit
Years After Treatment for HER2-Positive Early Stage Breast Cancer Trastuzumab Shows Life-Altering Benefit  JACKSONVILLE, Fla. — After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab (Herceptin) to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer. They found that the use of [...] (Source: Mayo Clinic Jacksonville News)
Source: Mayo Clinic Jacksonville News - October 21, 2014 Category: Hospital Management Source Type: news

Trastuzumab continues to show life for HER2-positve early stage breast cancer
(Mayo Clinic) After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 20, 2014 Category: Cancer & Oncology Source Type: news

Evaluation of the Dimerization Profiles of HER Tyrosine Kinases by Time-Resolved Förster Resonance Energy Transfer (TR-FRET)
Activation of receptor tyrosine kinases (RTK), such as those belonging to the human epidermal growth factor receptor (HER) family, occurs only after receptor dimerization, which is a crucial step for cellular signal transduction and diversification. The HER family includes four members (EGFR/HER1, HER2, HER3, and HER4) that can homodimerize or heterodimerize. Here, we describe immunoassays based on time-resolved Förster resonance energy transfer (TR-FRET) to profile EGFR-EGFR, HER2-HER2, and EGFR-HER2 dimers directly in tumor samples. (Source: Springer protocols feed by Protein Science)
Source: Springer protocols feed by Protein Science - October 17, 2014 Category: Biochemistry Source Type: news

Positive Findings for HER2-Negative Breast CancerPositive Findings for HER2-Negative Breast Cancer
Drs Fabrice André and Gunter von Minckwitz review potentially practice-changing and practice-confirming studies in HER2+ and HER2- breast cancer, presented at ESMO 2014. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 6, 2014 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Study Shows Roche's Perjeta Extended Lives of Breast Cancer Patients by 15.7 Months
Adding Perjeta to Herceptin and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 30, 2014 Category: Pharmaceuticals Source Type: news

Herceptin Best for Certain Breast Cancer Patients, Study Says
Drug should remain standard of care for HER2-positive tumors, doctors say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 30, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Oncology, Pharmacy, News, Source Type: news

Herceptin Best for Certain Breast Cancer Patients, Study Says
Drug should remain standard of care for HER2-positive tumors, doctors say (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - September 30, 2014 Category: Cancer & Oncology Source Type: news

Drug Gives Big Survival Boost Against Type of Advanced Breast Cancer
Women with HER2-positive tumors gained an average 16 more months of life with Perjeta, study finds (Source: WebMD Health)
Source: WebMD Health - September 29, 2014 Category: Consumer Health News Source Type: news

Trastuzumab should remain as standard of care for HER2-positive breast cancer, trial suggests
Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a researcher. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 29, 2014 Category: Science Source Type: news

Hopes for new breast cancer drug
A breast cancer drug could extend the lives of patients with an advanced form of the disease by almost five years, a study has found.Women with an aggressive type of cancer which has been traditionally hard to treat could benefit from using perjeta as a combination therapy with chemotherapy and herceptin, researchers said.A trial into the effectiveness of the combination of drugs found that survival among women with previously untreated advanced HER2-positive breast cancer was e (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - September 29, 2014 Category: Nursing Source Type: news

Trial shows trastuzumab should remain as standard of care for HER2-positive breast cancer
(Mayo Clinic) Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab, also known as Herceptin, should remain the standard of care for this cancer, says a Mayo Clinic researcher. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 29, 2014 Category: Cancer & Oncology Source Type: news

Trial Confirms That Perjeta Extends Survival In Metastatic Breast Cancer
Perjeta extends survival in patients with Her2 positive breast cancer. Might drugs targeting Her2 be effective in other malignancies? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 29, 2014 Category: Pharmaceuticals Authors: Elaine Schattner Source Type: news

A New Standard of Care in HER2 Breast Cancer
MADRID (MedPage Today) -- Adding two anti-HER2 agents to chemotherapy for metastatic disease increases media survival to almost 5 years. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 29, 2014 Category: Geriatrics Source Type: news

'Unprecedented' Survival of 15 Months Seen in CLEOPATRA'Unprecedented' Survival of 15 Months Seen in CLEOPATRA
Pertuzumab plus trastuzumab adds a 15-month survival benefit in HER2-positive metastatic breast cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 29, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Drug Gives Big Survival Boost Against Type of Advanced Breast Cancer
Women with HER2-positive tumors gained an average 16 more months of life with Perjeta, study finds (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 29, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Family Medicine, Gynecology, Nursing, Oncology, Pharmacy, News, Source Type: news

Roche’s Perjeta breast cancer drug shows extended survival benefit
Roche’s breast cancer drug Perjeta (pertuzumab) has shown extended survival benefits in patients with previously untreated HER2-positive metastatic breast cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 29, 2014 Category: Pharmaceuticals Source Type: news

Pertuzumab adds 16 months survival benefit to trastuzumab and chemotherapy treatment for HER2-positive metastatic breast cancer
Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 28, 2014 Category: Science Source Type: news

Roche Breast Cancer Drug Appears to Greatly Extend Patients’ Lives
Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer. (Source: NYT Health)
Source: NYT Health - September 28, 2014 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Clinical Trials Perjeta Drugs (Pharmaceuticals) Roche Holding AG Genentech Inc Herceptin (Drug) Breast Cancer HER2 Source Type: news

Roche Breast Cancer Drug Perjeta Appears to Greatly Extend Patients’ Lives
Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer. (Source: NYT Health)
Source: NYT Health - September 28, 2014 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Clinical Trials Perjeta Drugs (Pharmaceuticals) Roche Holding AG Genentech Inc Herceptin (Drug) Breast Cancer HER2 Source Type: news

Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy
Roche today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives (overall survival; OS) of people with previously untreated HER2-positive metastatic breast cancer (mBC) by 15.7 months compared to Herceptin and chemotherapy (median OS: 56.5 vs. 40.8 months). (Source: Roche Media News)
Source: Roche Media News - September 28, 2014 Category: Pharmaceuticals Source Type: news

Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy
Roche today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives (overall survival; OS) of people with previously untreated HER2-positive metastatic breast cancer (mBC) by 15.7 months compared to Herceptin and chemotherapy (median OS: 56.5 vs. 40.8 months). (Source: Roche Investor Update)
Source: Roche Investor Update - September 28, 2014 Category: Pharmaceuticals Source Type: news

Pertuzumab adds 16 months survival benefit to trastuzumab and chemo treatment for HER2-positive breast cancer
(European Society for Medical Oncology) Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 28, 2014 Category: Biology Source Type: news

Roche's Avastin and Xeloda show benefit for women with HER2-negative metastatic breast cancer in two new Phase III studies
Roche today announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following initial induction treatment with Avastin-based therapy resulted in clinically meaningful gains in overall survival (OS) and progression-free survival (PFS) in women with HER2-negative metastatic breast cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - September 25, 2014 Category: Pharmaceuticals Source Type: news

HER2 in Trastuzumab/Emtansine vs Trastuzumab/DocetaxelHER2 in Trastuzumab/Emtansine vs Trastuzumab/Docetaxel
What group of patients experience enhanced improvement from T-DM1 therapy? Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Breast Cancer Market (HER2-, HER2+) Epidemiology Forecast to 2023 in...
MarketOptimizer.org adds “EpiCast Report: Breast Cancer (HER2-, HER2+) – Epidemiology Forecast to 2023” to its store.(PRWeb September 10, 2014)Read the full story at http://www.prweb.com/releases/breast-cancer-her2-her2/market-outlook-to-2023/prweb12158564.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 11, 2014 Category: Pharmaceuticals Source Type: news

pCR and Improved Survival in Breast Cancer? pCR and Improved Survival in Breast Cancer?
Dr. Lidia Schapira discusses an analysis of NeoALTTO, which indicates that achieving pCR after neoadjuvant therapy for HER2+ cancer is associated with improved outcomes -- for some more than others. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

Early Data for HER2 Breast Ca Vax Promising
SAN FRANCISCO (MedPage Today) -- A cancer vaccine derived from HER2 protein demonstrated safety and preliminary evidence of activity in a randomized trial of patients with breast cancer. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 10, 2014 Category: Geriatrics Source Type: news

'Got It Right': Guidelines for HER2-Negative Breast Cancer'Got It Right': Guidelines for HER2-Negative Breast Cancer
Dr. Kathy Miller says the ASCO guidelines for advanced HER2-negative breast cancer 'got it right,' focusing on HT, sequential chemo agents, and decisions made jointly by doctors and patients. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. One of only a few vaccines of its kind in development, GP2 has been shown to be safe and effective for breast cancer patients, reducing recurrence rates by 57%. Further, women with the highest overexpression of HER2 (known as HER2 +3) had no cancer recurrences when they were administered the vaccine after completing trastuzumab (Herceptin), a type of immunotherapy drug known as a monoclonal antibody. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 5, 2014 Category: Science Source Type: news

Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients
(University of Texas M. D. Anderson Cancer Center) A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy in preventing disease recurrence. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 5, 2014 Category: Cancer & Oncology Source Type: news

Novel Immunotherapy Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients
A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - September 5, 2014 Category: Cancer & Oncology Source Type: news

ASCO Issues HER2-Negative Breast Cancer Guide
(MedPage Today) -- Hormonal therapy and sequential chemotherapy form the basis of systemic treatment for advanced HER2-negative breast cancer, according to a new clinical guideline. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 3, 2014 Category: Geriatrics Source Type: news

New ASCO Guideline for HER2-negative Advanced Breast CancerNew ASCO Guideline for HER2-negative Advanced Breast Cancer
The American Society of Clinical Oncology (ASCO) has issued a new guideline for the treatment of patients with HER2-negative advanced breast cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 3, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Guidelines for HER2-Negative Advanced Breast Cancer (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The American Society of Clinical Oncology has … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 3, 2014 Category: Primary Care Source Type: news